DexCom Inc. (D1EX34 SA) stock market data APIs
R$7.4566
-0.09(-1.2%)
as of June 5, 2026
Try our APIs with
free plan!
DexCom Inc. Financial Data Overview
Price chart is built with
Anychart
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Prev. Close
7.4566
Open
7.3636
High
7.4863
Low
7.3558
52 wk Range
5.75-10.06
Market Cap
144 124 M
P/E Ratio
31.125
Shares Outstanding
19 294 M
Revenue
4 818 M
Beta
1.443
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get DexCom Inc. data using free add-ons & libraries
Get DexCom Inc. Fundamental Data
DexCom Inc. Fundamental data includes:
- Net Revenue: 4 818 M
- EBITDA: 1 292 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
DexCom Inc. News
New
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world Dexcom sponsored CON...
Assessing DexCom (DXCM) Valuation After Recent Share Price Momentum
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Recent performance snapshot for DexCom (DXCM) With no single headline event dr...
Here's Why You Should Retain DexCom Stock in Your Portfolio
DexCom, Inc. DXCM is well-positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 performanc...
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
Dexcom reaffirms CGM benefits for all people with diabetes and continues momentum towards earlier stage intervention and preventative care at ADA 2026. Highly anticipated presentation of results from...
Get DexCom Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
